What is Cellay?
Cellay, Inc. is a biotechnology firm specializing in the development and manufacturing of Same Day OligoFISH Probes. These are short, chemically synthesized, and labeled oligonucleotides engineered for rapid hybridization, achieving results in as little as 5-10 minutes. The company leverages cGMP manufacturing standards and isothermal processing to offer clients an enhanced FISH (Fluorescence In Situ Hybridization) workflow. It is important to note that Cellay's probes are not FDA approved for cancer detection or diagnosis and are currently covered by pending patent applications. OligoFISH is a registered trademark of Cellay, Inc.
How much funding has Cellay raised?
Cellay has raised a total of $292K across 2 funding rounds:
Debt
$150K
Debt
$142K
Debt (2020): $150K with participation from PPP
Debt (2021): $142K led by PPP
Key Investors in Cellay
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Cellay?
With its recent large-scale, late-stage funding, Cellay is poised to accelerate its growth and scale its operations. The strategic investment will likely fuel further research and development, enhance manufacturing capabilities, and expand market reach for its rapid hybridization probes. The company's focus on improving FISH workflows suggests a strategic push towards clinical diagnostics and research applications, aiming to capture a significant share of the molecular diagnostics market. Future developments may include broader regulatory approvals and strategic partnerships to integrate their technology into mainstream diagnostic platforms.
See full Cellay company page
